INVO Fertility Appoints New CFO
INVO Fertility announced changes to its executive leadership team. Terah Krigsvold, who has served as INVO's controller since December 2020, has been appointed as the company's new chief financial officer, replacing Andrea Goren. Goren, who has served as INVO chief financial officer since July 2021, has been appointed as chief business officer, as well as chief executive officer of INVO Centers LLC, the company's wholly owned subsidiary focused on fertility clinics. "As we continue to grow our presence in the fertility sector and based on Terah and Andrea's commitment, hard work and growth over the past five years, this realignment of roles strengthens our ability to execute our plan to grow the business and reach profitability," said Steve Shum, CEO of INVO. "I have worked with Terah for the past seven years and am thrilled at the progress she has demonstrated over that time. This promotion is very well deserved and ensures continuity, as well as keeping our finance and accounting functions in a strong pair of hands. With this change, Andrea is now able to focus more of his time on leading the execution of our primary growth strategy, acquisitions, and, in due course, new clinic launches. Andrea has worked on approximately $1 billion of financing and acquisition transactions in his career and is ideally suited to manage the negotiations and complex legal and diligence aspects of our acquisition and new clinic efforts. Andrea also will continue in his roles of managing our legal function and supporting our investor, shareholder, and related activities."
Trade with 70% Backtested Accuracy
Analyst Views on IVF
About IVF
About the author

INVO Fertility Enters Warrant Inducement Agreement with Investor
- Financing Agreement: INVO Fertility has signed a warrant inducement agreement with an investor, who will immediately exercise 4,733,728 warrants at a revised price of $1.59 per share, expected to raise approximately $7.5 million, enhancing the company's liquidity for future growth.
- New Warrant Issuance: As part of the agreement, the company will issue 9,467,456 new warrants to the investor at the same exercise price of $1.59, subject to shareholder approval, which is expected to further strengthen the company's capital structure and market appeal.
- Registration Statement Filing: INVO Fertility will file a registration statement with the SEC to cover the resale of common stock upon exercise of the new warrants, ensuring compliance and paving the way for future capital operations.
- Market Strategy Enhancement: Through this financing and the issuance of new warrants, INVO Fertility aims to expand its influence in the assisted reproductive technology market, further driving the development of its INVO Centers and enhancing the company's competitiveness in the fertility healthcare sector.

General Motors Reports Strong Q4 Earnings and Dividend Increase
- Earnings Beat: General Motors reported fourth-quarter adjusted earnings per share of $2.51, a 30.4% year-over-year increase that surpassed analyst expectations of $2.20, indicating a significant improvement in profitability.
- Sales Miss: The company's quarterly sales reached $45.287 billion, falling short of the market expectation of $45.804 billion, reflecting challenges from increased market competition and demand fluctuations.
- Dividend Increase: The Board of Directors approved a 3-cent increase in the quarterly common stock dividend to 18 cents per share, demonstrating confidence in future cash flows and commitment to shareholder returns.
- Share Repurchase Program: GM announced a new $6 billion share repurchase authorization aimed at enhancing earnings per share by reducing the number of shares outstanding, thereby boosting investor confidence.






